{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008452","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.546555+00:00","generated_at":"2026-06-18T00:48:39.822897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023","bullets":["Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).","Cash and investments total $354.9M; management expects runway to fund operations into 2025.","R&D expenses $90.9M (FY) and $26.8M (Q4); G&A $28.1M (FY) and $8.1M (Q4).","NKX101: 60% CR in AML at higher doses; additional data expected H1 2023.","NKX019: 70% CR in B-cell malignancies; dose expansion enrolling; updated data expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008452","json":"https://secwatch.observer/filing/0000950170-23-008452.json","markdown":"https://secwatch.observer/filing/0000950170-23-008452.md","text":"https://secwatch.observer/filing/0000950170-23-008452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/0000950170-23-008452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/nktx-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:48:39.822897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}